A Universal Single‐Activated‐Dual‐Release Vehicle: Enabling Synergistic Antitumor Therapy
Small · 2025
DOI: 10.1002/smll.202410925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2025. Verfasst von Jinliang Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Fine Chemicals, Frontier Science Center for Smart Materials, Dalian University of Technology, Dalian, 116023, China. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Liaoning Binhai Laboratory, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Activatable combined therapeutic strategy exhibits significant potential for the management of malignant tumors. Ensuring the timely and spatially effective release of different therapeutic agents is a great challenge for maximizing the efficacy of combination therapy. Herein, based on the 1,4‐and 1,6‐elimination behaviors, the study proposes a novel universal single‐activated‐dual‐release platform that can be triggered by various stimulants of interest. As a proof‐of‐concept, the study develops an example of a synergistic therapy called CyI‐Cbl‐NTR , which can be selectively activated by nitroreductase (NTR) to release the photosensitizer ( CyI‐OH ) and DNA alkylating agent chlorambucil (Cbl), thereby enabling a combination of chemo‐ and photodynamic therapy. Both in vitro and in vivo experiments fully demonstrate the remarkable combined therapeutic effect of Cyl‐Cbl‐NTR and the feasibility of this strategy. This work provides a promising platform for the future development of activatable synergistic therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Fine Chemicals, Frontier Science Center for Smart Materials, Dalian University of Technology, Dalian, 116023, China.
- Liaoning Binhai Laboratory, Dalian, 116023, China.
ORCID-Profile: Jiangli Fan
Förderung
- National Natural Science Foundation of China
- Liaoning Binhai Laboratory
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Han, J., Yang, M., Li, K., Liu, W., Fan, J., & Peng, X. (2025). A Universal Single‐Activated‐Dual‐Release Vehicle: Enabling Synergistic Antitumor Therapy. Small. https://doi.org/10.1002/smll.202410925
Vancouver
Han J, Yang M, Li K, Liu W, Fan J, Peng X. A Universal Single‐Activated‐Dual‐Release Vehicle: Enabling Synergistic Antitumor Therapy. Small. 2025. doi:10.1002/smll.202410925
BibTeX
@article{Han2025,
author = {Han, Jinliang and Yang, Mingwang and Li, Kang and Liu, Wenkai and Fan, Jiangli and Peng, Xiaojun},
title = {A Universal Single‐Activated‐Dual‐Release Vehicle: Enabling Synergistic Antitumor Therapy},
journal = {Small},
year = {2025},
doi = {10.1002/smll.202410925}
}
EUVIMED